Page 78 - PCC11

IVM IMPROVED – BUT CLINICAL TRIALS ARE NEEDED!
Page 72 of 155
17
FOR WHOM WOULD IT BE FEASIBLE?
 IVM requires no or small doses of gonadotropins and does not imply the growth of follicles to a large size. Therefore it can totally abolish the risk of OHSS.
 PCO and PCOs patients have become the first natural candidates for IVM treatment and has been performed as early as 1994 (Trounson et al., 1994).
 Patients with ovarian resistance to FSH (Grynberg et al., 2012).
 Oncological patients in connection with fertility preservation.
 Normal IVF-patients could benefit...
18
78